Potential role of sorafenib in the treatment of acute myeloid leukemia

被引：51

作者：

Mori, Shahram ^{[1
]}

Cortes, Jorge ^{[1
]}

Kantarjian, Hagop ^{[1
]}

Zhang, Weiguo ^{[2
]}

Andreef, Michael ^{[2
]}

Ravandi, Farhad ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Unit 428, Houston, TX 77030 USA

[2] Univ Texas MD Anderson Canc Ctr, Stem Cell Transplantat & Cellular Therapy, Sect Mol Hematol & Therapy, Houston, TX 77030 USA

来源：

LEUKEMIA & LYMPHOMA | 2008年 / 49卷 / 12期

关键词：

AML; FLT3; mutations; MAP kinase signalling; sorafenib;

D O I：

10.1080/10428190802510349

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The identification of aberrant cellular pathways and dysfunctional molecules important in neoplastic transformation has begun to provide us with a number of targets for drug development. It is likely that many of these agents will be incorporated into our existing treatment strategies that include cytotoxic agents. Sorafenib, a multi-kinase inhibitor has been approved in the United States for the treatment of renal cell carcinoma as well as hepatocellular cancer. Its potential role in hematological malignancies, particularly acute myeloid leukemia (AML) is under evaluation. Here we describe the biological pathways in AML that are the potential targets of sorafenib action and discuss the early clinical data with the agent in solid tumors and AML.

引用

页码：2246 / 2255

页数：10

共 77 条

[1] Ways of dying: multiple pathways to apoptosis [J].

Adams, JM .

GENES & DEVELOPMENT, 2003, 17 (20) :2481-2495

[2] Antitumor activity of sorafenib in FLT3-driven leukemic cells [J].

Auclair, D. ;

Miller, D. ;

Yatsula, V. ;

Pickett, W. ;

Carter, C. ;

Chang, Y. ;

Zhang, X. ;

Wilkie, D. ;

Burd, A. ;

Shi, H. ;

Rocks, S. ;

Gedrich, R. ;

Abriola, L. ;

Vasavada, H. ;

Lynch, M. ;

Dumas, J. ;

Trail, P. A. ;

Wilhelm, S. M. .

LEUKEMIA, 2007, 21 (03) :439-445

[3]

BAINES P, 2000, EUR J HAEMATOL, V211

[4] Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms [J].

Bonni, A ;

Brunet, A ;

West, AE ;

Datta, SR ;

Takasu, MA ;

Greenberg, ME .

SCIENCE, 1999, 286 (5443) :1358-1362

[5]

BREITENBUECHER F, BLOOD

[6] Stat3 as an oncogene [J].

Bromberg, JF ;

Wrzeszczynska, MH ;

Devgan, G ;

Zhao, YX ;

Pestell, RG ;

Albanese, C ;

Darnell, JE .

CELL, 1999, 98 (03) :295-303

[7] LOCALIZATION OF THE HUMAN STEM-CELL TYROSINE KINASE-1 GENE (FLT3) TO 13Q12-]Q13 [J].

CAROW, CE ;

KIM, E ;

HAWKINS, AL ;

WEBB, HD ;

GRIFFIN, CA ;

JABS, EW ;

CIVIN, CI ;

SMALL, D .

CYTOGENETICS AND CELL GENETICS, 1995, 70 (3-4) :255-257

[8] Variable sensitivity of FLT3 activation loop mutations to the small molecule tyrosine kinase inhibitor MLN518 [J].

Clark, JJ ;

Cools, J ;

Curley, DP ;

Yu, JC ;

Lokker, NA ;

Giese, NA ;

Gilliland, DG .

BLOOD, 2004, 104 (09) :2867-2872

[9] Renal-cell carcinoma [J].

Cohen, HT ;

McGovern, FJ .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (23) :2477-2490

[10] Prediction of resistance to small molecule FLT3 inhibitors: Implications for molecularly targeted therapy of acute leukemia [J].

Cools, J ;

Mentens, N ;

Furet, P ;

Fabbro, D ;

Clark, JJ ;

Griffin, JD ;

Marynen, P ;

Gilliland, DG .

CANCER RESEARCH, 2004, 64 (18) :6385-6389

← 1 2 3 4 5 6 7 8 →